National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of Site Contamination) Measure 1999 National Environment Protection (Assessment of

Schedule B7

APPENDIX A2

The Derivation of HILs for  
PAHs and Phenols

Page

**Contents**

**The derivation of HILs for PAHs and phenols**

1 Benzo(a)pyrene 1

1.1 General 1

1.2 Previous HIL 2

1.3 Significance of Exposure Pathways 2

1.3.1 Oral Bioavailability 2

1.3.2 Dermal absorption 3

1.3.3 Inhalation of Dust 3

1.3.4 Plant Uptake 3

1.3.5 Intakes from Other Sources – Background 4

1.4 Identification of Toxicity Reference Values 4

1.4.1 Classification 4

1.4.2 Review of Available Values/Information 4

1.4.2.1 Note on Dermal Exposures 6

1.4.3 Recommendation 7

1.5 Calculated HILs for BaP and Carcinogenic PAHs (as BaP TEF) 7

1.6 Calculated HILs for Total PAHs 8

1.7 References 9

2 Phenol 12

2.1 General 12

2.2 Previous HIL 12

2.3 Significance of Exposure Pathways 12

2.3.1 Oral Bioavailability 12

2.3.2 Dermal absorption 13

2.3.3 Inhalation of Dust 13

2.3.4 Plant Uptake 13

2.3.5 Intakes from Other Sources – Background 13

2.4 Identification of Toxicity Reference Values 14

2.4.1 Classification 14

2.4.2 Review of Available Values/Information 14

2.4.3 Recommendation 16

2.5 Calculated HILs 16

2.6 References 17

3 Pentachlorophenol (PCP) 18

3.1 General 18

3.2 Previous HIL 18

3.3 Significance of Exposure Pathways 18

3.3.1 Oral Bioavailability 18

3.3.2 Dermal absorption 18

3.3.3 Inhalation of Dust 19

3.3.4 Plant Uptake 19

3.3.5 Intakes from Other Sources – Background 19

3.4 Identification of Toxicity Reference Values 19

3.4.1 Classification 19

3.4.2 Review of Available Values/Information 20

3.4.3 Recommendation 21

3.5 Calculated HILs 21

3.6 References 22

4 Total Cresols 23

4.1 General 23

4.2 Previous HIL 23

4.3 Significance of Exposure Pathways 23

4.3.1 Oral Bioavailability 23

4.3.2 Dermal absorption 23

4.3.3 Inhalation of Dust 23

4.3.4 Plant Uptake 23

4.3.5 Intakes from Other Sources – Background 24

4.4 Identification of Toxicity Reference Values 24

4.4.1 Classification 24

4.4.2 Review of Available Values/Information 24

4.4.3 Recommendation 25

4.5 Calculated HILs 25

4.6 References 26

5 Shortened forms 27

# Benzo(a)pyrene

## General

Several comprehensive reviews of polycyclic aromatic hydrocarbons (PAHs) and benzo(a)pyrene (BaP) in the environment and their toxicity to humans are available and should be consulted for more detailed information not presented in this summary (ATSDR 1995; WHO 1998; CCME 2008). The following provides a summary of the key aspects of these compounds that are relevant to the derivation of a soil HIL.

PAHs are a large group of organic compounds with two or more fused aromatic rings made up of carbon and hydrogen atoms. PAHs are formed from incomplete combustion of organic materials such as the processing of coal, crude oil, combustion of natural gas, refuse, vehicle emissions, heating, cooking and tobacco smoking, as well as natural processes including carbonisation. The natural background level is due to PAH production in plant species. Because of such widespread sources, PAHs are present almost everywhere. Food is considered to be the major source of human exposure to PAH, due to the formation of PAH during cooking or from atmospheric deposition of PAHs on grains, fruits and vegetables (WHO 1998).

There are several hundred PAHs, including derivatives of PAHs. The best known (and studied) is BaP. While there are hundreds of PAHs, typically only 16 individual PAHs are analysed in site contamination investigations. These individual PAHs address a broad range of the equivalent carbon spectrum and are therefore more commonly reported and assessed (where there is more data available on these PAHs).

The major sources of PAHs to soils at any given location invariably contribute a mixture of PAHs, not just single compounds. Various PAH source types can be distinguished based on the characteristic compositions of PAH mixtures and information on the site history, but the contaminated soil matrix is nonetheless challenging from an environmental risk assessment perspective, since in a PAH-contaminated soil there is likely to be a diverse compositional range of non-carcinogenic and carcinogenic PAHs of varying potency.

The major approach advocated by regulatory agencies such as the NEPC (NEPC 1999; Fitzgerald 1991; Fitzgerald 1998), California EPA (OEHHA), Netherlands (RIVM 2001), England and Wales (DEFRA & EA 2002), Canada (CCME 2008) and US EPA (2010 draft) for assessing the human health risks of PAH-containing mixtures involves the use of toxicity equivalence factors (TEFs). This approach relates the toxicity of other (potentially carcinogenic) individual PAHs relative to that of BaP, the most widely studied PAH.

There are more than a dozen sets of equivalency numbers that have been proposed over the last two decades. The most recent (published final) review of TEF and their basis, presented by CCME (2008), suggests the use of TEF recommended by the World Health Organization (WHO 1998), with minor modifications. This is a scheme based on the order-of-magnitude cancer potency.

Any finer-scale assertions about relative potency for more generic application are hard to justify given the current state of knowledge and confounding influences such as the route of exposure or non-additive effects in complex PAH mixtures. It is not currently possible to develop different relative potency schemes across different exposure routes (oral, dermal, inhalation), owing to a lack of data. Hence the TEFs adopted have been applied for all routes of exposure for the carcinogenic PAHs assessed. Application of the TEFs is relevant to the assessment of PAHs that are considered to be carcinogenic. Other PAHs that are not carcinogenic should be assessed separately on an individual basis.

The following table presents a summary of the TEFs adopted for the assessment of carcinogenic PAHs (CCME 2008):

|  |  |  |  |
| --- | --- | --- | --- |
| PAH | IARC Classification | US EPA Classification | TEF |
| Benzo(a)anthracene | 2B | B2 | 0.1 |
| Benzo(a)pyrene | 1 | B2 | 1 |
| Benzo(b+j)fluoranthene | 2B | B2 | 0.1 |
| Benzo(k)fluoranthene | 2B | B2 | 0.1 |
| Benzo(g,h,i)perylene\* | 3 | D | 0.01 |
| Chrysene | 2B | B2 | 0.01 |
| Dibenz(a,h)anthracene | 2A | B2 | 1 |
| Indeno(1,2,3-cd)pyrene | 2B | B2 | 0.1 |

Notes: 1/A= Human Carcinogen, 2A/B2= Probable Human Carcinogen, 2B/C=Possible Human Carcinogen, 3/D= Not classifiable.

\* Benzo(g,h,i)perylene included due to positive findings in genotoxicity studies (WHO 1998). Note there is insufficient data available to determine carcinogenicity.

The toxic effects of different PAH compounds in a mixture are additive. Experimental evidence suggests that this is a fair assumption (Fitzgerald 1991; Fitzgerald 1998; CCME 2008).

The following relates to the approach used to assess BaP in the derivation of HILs (which can be used for the assessment of BaP alone or for carcinogenic PAHs using the above TEFs).

## Previous HIL

The derivation of the previous HIL (HIL A = 1 mg/kg) for BaP is presented by Fitzgerald (1991) and NEPC (1999). In summary, the HIL was derived on the basis of the following:

* Intakes associated with daily exposure by children and adults living near or on soil containing 1 mg/kg BaP were assessed on the basis of:
  + Dermal absorption, with 1% BaP absorbed via the skin
  + Ingestion, with 100% bioavailability assumed
  + Inhalation, over 24 hours, with 100% bioavailability assumed.
* In comparison to background intakes of BaP, intakes from soil at 1 mg/kg are low but higher intakes may be nearing a significant contribution. Adoption of 1 mg/kg was considered appropriate also due to the potential for further review by S EPA where reference values for BaP may change.

Further review of BaP (and PAHs using TEFs) by Fitzgerald (1998) and Fitzgerald et al. (2004), on the basis of a derived modified benchmark dose, calculated a value of 5 mg/kg on the basis of soil ingestion only.

## Significance of Exposure Pathways

### Oral Bioavailability

A study by Hansen et al. (2007) demonstrated bioavailability of PAHs in three different soil samples ranging from 14− 40% using an in vitro bioavailability model that simulates gastric digestion. In addition, the Massachusetts DEP uses a relative absorption fraction of 28% for PAHs (MADEP 2008) in its risk assessment program. In addition it is noted that BaP (and PAHs) present in bitumen fragments are largely immobile and typically have a low bioavailability. However, as bioavailability is highly site- and source-specific, insufficient data is available to adequately define a value that differs from the default approach of 100% oral bioavailability. It is noted that a site-specific assessment of bioavailability can be undertaken where required.

### Dermal absorption

Review of dermal absorption of BaP has been conducted by MfE (2011). This review has identified the following, based on studies on animals and humans (rather than modelled as presented by CCME (2008)):

* As BaP is actively metabolised in the skin, it is relevant to include both the amount that passes through the skin and that which remains bound to the skin to estimate dermal uptake.
* US EPA (2004) recommends a dermal absorption factor of 0.13 (13%), which is based on data from Wester et al. (1990). These authors indicate that 13.2% of BaP in soil was absorbed by rhesus monkeys over a 24-hour period. However, they also indicate that a reduced amount (1.4%) was absorbed into human skin from soil over the same time period, although no partitioning into human plasma occurred, i.e. the BaP remained bound to the skin.
* Another study on the dermal absorption of BaP from soils also showed that a minimal amount (0.1%) of BaP was absorbed through pig skin and 1.7% and 3.5% remained bound to the skin when BaP respectively in aged sandy and clay soils was applied to the skin (Abdel-Rahman et al. 2002). A higher amount (3.3% and 8.3% in clay and sandy soils, respectively) was absorbed when non-aged soil (i.e. freshly spiked) was applied to the skin.
* A more recent study with human skin showed greater absorption through the skin, with approximately 7% of BaP passing through when applied as freshly spiked soil (Moody et al. 2007). A further 7% remained bound to the skin.
* As ageing soils decrease the bioavailability of BaP, the dermal absorption data from freshly spiked soils can provide a worst-case estimate of dermal absorption. The geometric mean of dermal absorption using freshly spiked soils from the above studies (including in vivostudies) is 6%, while using data for aged soils yields a geometric mean of 2.6% (Abdel-Rahman et al. 2002).

Review by MfE (2011) resulted in the adoption of a dermal absorption factor of 2.6%, the arithmetic mean of data from aged soil (Abdel-Rahman et al. 2002). In the derivation of soil HILs in this review, the higher arithmetic mean value of 6% (based on data from freshly spiked soil and noted by MfE (2011) as a worst-case value that is supported by studies from Wester et al. (1990), Abdel-Rahman et al. (2002) and Moody et al. (2007)) has been adopted and is considered relevant for all source types.

### Inhalation of Dust

BaP (and other carcinogenic PAHS) are not considered sufficiently volatile to be of significance and inhalation exposures associated with particulates outdoors and indoors are expected to be of less significance than ingestion of soil. Exposure via inhalation of dust is estimated to be less than 1% of the total exposure.

### Plant Uptake

CCME (2008) notes that concentrations of PAHs in uncooked produce depend principally on its source. Plants grown on PAH-contaminated soils, however, have only a limited ability to take in through the roots and translocate anthropogenic PAHs to the aboveground plant biomass—especially for higher molecular weight PAHs. One mode of plant contamination is via the deposition of PAH-containing fine particulates onto plant surfaces.

PAHs may be bound within soils (via lignification), mineralised (ultimately to CO2 and water) or metabolised outside or within the plant (CCME 2008). Higher molecular weight PAHs such as BaP (and other carcinogenic PAHs) are considered persistent and are strongly absorbed to the soil. Lipophilic organic compounds such as PAHs (and BaP), with a low solubility in water, high Henry’s law constant and high Kow(>104), are bound strongly to the root surface and/or soils and are not readily translocated within plants (Schnoor 1997). These generally tend to partition into the epidermis or outer layers of the root tissue (or peel) and remain there bound to lipids in cell walls; transfer into the inner root or xylem is very slow or non-existent. CCME (2008) notes that the general consensus in the literature is that the root uptake pathway of organic contaminants such as hydrocarbons and PAH constituents from the soil by plants is extremely limited, particularly for the heavier PAHs such as BaP.

On the basis of the above, plant uptake has not been considered in the derivation of HIL A. However it is noted that if plant uptake were considered (using the equations presented in Appendix B), intakes derived from this source are low and do not significantly contribute to the HIL (<1%).

### Intakes from Other Sources – Background

Intakes of BaP from sources other than soil have been considered by Fitzgerald (1991) to range from 0.166−1.6 µg/day (US EPA 1980) with intakes derived from food identified as the most significant. While more detailed reviews are available on potential intakes of BaP (CCME 2008), background intakes are not considered in the derivation of an HIL for BaP, as a non-threshold approach has been adopted.

## Identification of Toxicity Reference Values

### Classification

The International Agency for Research on Cancer (IARC 2010) has classified BaP as   
1—human carcinogen.

The US EPA has classified BaP as B2—probable human carcinogen.

### Review of Available Values/Information

BaP has been shown to be carcinogenic via all routes of exposure. BaP is an indirect carcinogen, that is, its carcinogenicity results from its metabolites, primarily various epoxides, as opposed to BaP itself. Several different types of tumours have been observed as a result of exposure to BaP, although tumour development is closely related to route of administration, i.e. dermal application induces skin tumours and oral administration induces gastric tumours. Exposure to BaP causes disruption to cellular genetic material, in particular DNA adducts are formed as a result of exposure and BaP is considered to be a genotoxic carcinogen (WHO 1998).

In addition BaP has been demonstrated to be a skin irritant and dermal sensitiser (WHO 1998).

US EPA (2005) has concluded that BaP (and carcinogenic PAHs assessed on the basis of a TEF) acts via a mutagenic mode of action and recommends that susceptibility associated with early lifetime exposures be addressed. No non-threshold values available for BaP have been derived to specifically address early lifetime susceptibility and hence these issues may need to be addressed when characterising exposure to BaP.

On this basis, a peer-reviewed non-threshold reference value is recommended for BaP. The following non-threshold values are available from Level 1 Australian and International sources:

| **Source** | **Value** | **Basis/Comments** |
| --- | --- | --- |
| **Australian** | | |
| ADWG (NHMRC 2011) | Not available | Current guideline of 0.00001 mg/L established in ADWG (NHMRC 2011) is based on the consideration of health effects in relation to the limit of determination for analysis. The assessment provided by the WHO is noted. |
| OCS (2012) | No evaluation available |  |
| **International** | | |
| WHO (2011) | SF = 0.5 (mg/kg/day)-1  UR =8.7x10-5 (ng/m3)-1 | WHO (2011) derived a drinking water guideline of 0.0007 mg/L on the basis of an excess lifetime cancer risk of10-5 from an oral carcinogenicity study (Neal & Rigdon 1967) and a two-stage birth−death mutation model. Slope factor has been calculated on the basis of a 70 kg adult and consumption of 2 L water per day.  Inhalation UR derived (WHO 2000 and 2010) based on observations in coke oven workers to mixtures of PAHs. It is noted that the composition of PAHs to which coke oven workers are exposed may differ from that present in ambient air, or derived from soil contamination. It is noted that an inhalation UR is in the same order of magnitude as that derived using a linear multistage model associated with lung tumours in a rat inhalation study of coal tar/pitch condensation aerosols. |
| MfE (2011) | SF = 0.233 (mg/kg/day)-1 | Review of the carcinogenic reference values available for oral intakes by MfE (2011) considered the range of values available and differences in approaches adopted for low dose extrapolation. The application of cross-species scaling appeared to be the most significant factor affecting the cancer potency estimates. It was recommended that cross-species scaling should not be applied, consistent with the approach outlined in NHMRC (1999). Review of available studies (14 risk estimates using 4 databases) resulted in the calculation of a geometric mean based on data without scaling that was recommended for use in the derivation of a soil guideline value. |
| EA (2002) | Derived index doses from WHO evaluations | Oral index dose derived on the basis of WHO approach and a lifetime cancer risk of 10-5.  Inhalation index dose based on WHO approach and adopting an air guideline of 0.25 ng/m3. The air guideline is equivalent to a lifetime cancer risk of 4x10-5. |
| RIVM (2001) | SF = 0.2 (mg/kg/day)-1 | Oral SF derived by RIVM based on a chronic oral carcinogenic rat study and linear multistage model. The study considered was more recent than that considered by WHO. No inhalation assessment is provided by RIVM. |
| CCME (2008) | SF = 2.3 (mg/kg/day)-1 | Oral SF derived from a less than lifetime diet study on inbred CFW-Swiss mice associated with incidence of papillomas and squamous cell carcinomas and linear extrapolation. This is the same study as used by US EPA in the derivation of its oral slope factor. The CCME review also noted that dermal exposures and primary oral exposures result in different kinds of cancers. Health Canada is currently reviewing data with respect to the derivation of a dermal cancer slope factor, which may require consideration when peer-reviewed and published. The oral slope factor has been used to derive a soil guideline associated with exposures via oral, dermal and inhalation exposures. |
| OEHHA (CEPA 1999) | SF = 11.5 (mg/kg/day)-1  UR =0.0011 to0.0033 (ug/m3)-1 | Oral SF derived using the same model and study as reported by US EPA (IRIS 2012) and CCME (2008), with the upper end of the range of values adopted by OEHHA.  Inhalation UR derived on the basis of respiratory tract tumours in an inhalation study in hamsters and a linearised multistage model. |
| US EPA (IRIS 2012) | SF = 7.3 (mg/kg/day)-1 | Oral SF (last reviewed in 1994) derived on the basis of the same study considered by CCME (above) where a range of slope factors was derived (4.5 to 11.7 (mg/kg/day)-1). The geometric mean was adopted as the recommended slope factor for derivation of a drinking water guideline. No assessment of inhalation toxicity is available. |

There is a wide range of non-threshold reference values available for oral intakes of BaP. The most recent review, where the methodology used for low dose extrapolation was reviewed, was conducted by MfE (2011). The evaluation presented considered all the available and relevant studies noted in the above tables and identified an oral reference value based on the geometric mean. This value is considered appropriate for the derivation of HILs. However it is noted that the reference document remains a draft at the time of preparation of this evaluation, hence additional consideration of a finalised peer-reviewed reference value has also been presented.

Based on the available published peer-reviewed sources, the oral reference value presented in the WHO DWG (2011) can also be considered (remains current and relevant) in the derivation of soil HILs. The WHO oral reference value is similar to the value derived by RIVM (2001) and has been adopted by EA (2002).

The data available on inhalation exposures is dominated by occupational studies associated with exposure to coke oven emissions or coal tar pitch aerosols. BaP is not volatile and hence the relevance of these studies to the assessment of dust issues derived from contaminated sites is not clear. It is therefore recommended that the WHO oral reference value be considered for the assessment of all pathways of exposure.

#### Note on Dermal Exposures

BaP is suggested to act largely as a point-of-contact carcinogen (Knafla et al. 2006), as opposed to systemically, hence it is more appropriate to derive soil guideline values for the dermal route of exposure using a route-specific slope factor, as opposed to consideration on the basis of systemic absorption and use of the oral slope factor.

For most compounds such data is not available but for BaP, Knafla et al. (2011) have derived a dermal slope factor, normalised to a per unit skin surface area basis, that is relevant to the assessment of BaP in soil in skin. The dermal slope factor of 3.5 (µg/cm2/day)-1 was derived by Knafla et al. (2011) and appropriate methods and parameters have been suggested for the use of this factor in the assessment of soil exposures. The dermal slope factor is an extension of previous work published by Knafla et al. (2006), where a dermal slope factor was derived on the basis of skin carcinogenicity from skin painting studies with mice. The revised dermal slope factor (Knafla et al. 2011) considered various factors for interspecies extrapolation, particularly in relation to sensitivity (to tumour development) and differences in epidermal (target tissue) thickness. This dermal slope factor has not yet been adopted for use by other international agencies, however CCME (2008) indicate that Health Canada may consider the revised dermal slope factor once published (as occurred in 2011).

The dermal slope factor as proposed by Knafla et al. (2011) has been considered in the derivation of the HIL for BaP, in addition to the use of the oral TRV. The calculations have been conducted for garden soil using default values presented by Knafla et al. (2011) for loading rates and epidermal thickness.

### Recommendation

On the basis of the discussion above, the following toxicity reference values (TRVs) have been adopted for BaP in the derivation of HILs:

**Recommendation for BaP and carcinogenic PAHs as BaP TEF**

Oral TRV (TRVO) = 0.233 (mg/kg/day)-1 (MfE 2011) for all routes of exposure

Value has been compared with TRVO = 0.5 (mg/kg/day)-1 (WHO 2011) for all routes of exposure

Dermal absorption factor (DAF) = 0.06 (or 6%) (MfE 2011)

BaP equivalents to be determined for carcinogenic and potential genotoxic PAHs only using TEFs presented by CCME (2008)

Note: early lifetime exposures to BaP may need to be addressed in the quantification of exposure as per US EPA (2005).

## Calculated HILs for BaP and Carcinogenic PAHs (as BaP TEF)

It is noted that the discussion above has identified that further consideration of early lifetime exposures to BaP may need to be considered in the quantification of exposure (calculated as per US EPA 2006). Other uncertainties have also been noted in the above discussion, particularly in relation to the selection of the oral TRV (where the value from MfE (2011) may also be considered, although it is a draft) and dermal exposures.

With respect to the derivation of HIL A, the following can be noted:

* HIL A = 20 mg/kg on the basis of the recommended oral TRV from MfE (2011) (also adopted for dermal exposures) and no additional consideration of early-lifetime exposures.
* HIL A = 8 mg/kg on the basis of the oral TRV from WHO (2011) (also adopted for dermal exposures) and no additional consideration of early-lifetime exposures.
* HIL A = 6 mg/kg on the basis of the recommended oral TRV from MfE (2011) (also adopted for dermal exposures) and consideration of early-lifetime exposures[[1]](#footnote-1);
* HIL A = 3 mg/kg on the basis of the oral TRV from WHO (2011) and consideration of early-lifetime exposures1.
* HIL A = 0.3 mg/kg on the basis of the recommended oral TRV from MfE (2011), but consideration of the dermal slope factor presented by Knafla et al. (2011) and no consideration of early lifetime exposures. Note that the HIL is lower (0.1 mg/kg) if early lifetime exposures are assessed for oral intakes.

With consideration of the uncertainties (particularly in relation to the assessment of dermal exposures) identified and the effect of these on the derived HIL A value (noted above), it is recommended that the lower value derived on the basis of the WHO (2011) oral TRV (also adopted for dermal exposures) with consideration of early-lifetime exposures (for HILs A, B and C only), that results in the calculation of HIL A = 3 mg/kg, be adopted.

It is noted that while the approach adopted for the derivation of the HILs has not directly incorporated the dermal approach outlined by Knafla et al. (2011), individual jurisdictions may require consideration of these issues in a site-specific assessment, particularly where people may come into direct contact with coal tar.

On this basis, the following HILs are recommended for BaP and carcinogenic PAHs (assessed as BaP TEF) (refer to Appendix B for equations used to calculate the HILs and Appendix C for calculations):

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HIL Scenario** | **HIL\* (mg/kg)** | **Percentage Contribution from Exposure Pathways** | | | |
| **Ingestion of Soil/Dust** | **Ingestion of Home-grown Produce** | **Dermal Absorption of Soil/Dust** | **Inhalation (dust)** |
| Residential A | 3 | 46 | -- | 54 | <1 |
| Residential B | 4 | 17 | -- | 83 | <1 |
| Recreational C | 3 | 29 | -- | 71 | <1 |
| Commercial D | 40 | 18 | -- | 82 | <1 |

-- Pathway not included in derivation of HIL

\* Noted that as the dermal absorption pathway dominates the derivation of HILs A, B and C and the exposure assumptions differ little between these scenarios, the HIL remains essentially unchanged. Note derived HILs to 2 significant figures presented in brackets.

Elevated levels of BaP in relatively immobile sources, such as bitumen fragments, do not represent a significant health risk.

## Calculated HILs for Total PAHs

The derived HILs above relate to BaP and carcinogenic PAHs calculated on the basis of a BaP TEF (refer to Section 2.2 of Schedule B(7)). However, there are several hundred PAHs, including derivatives of PAHs of which typically only 16 individual PAHs are analysed in site contamination investigations. These individual PAHs have been identified as the most significant based on: the amount of information available on each individual PAH; the toxicity (suspected to be more harmful than other PAHs), there is a greater chance of being exposed to these PAHs; and of all the PAHs analysed, the 16 selected are the most commonly reported at contaminated sites.

Hence to assist in the assessment of contaminated sites it is relevant to also consider total PAHs. Of the PAHs reported these will comprise BaP and carcinogenic PAHs and other non-carcinogenic PAHs where the following can be noted with respect to the derivation of HILs:

* BaP and carcinogenic PAHs assessed as BaP TEF should be assessed on the basis of the above HILs.
* Naphthalene is the most significant volatile PAH and therefore the assessment of this compound should address all significant pathways of concern, including vapour inhalation (not addressed in the HIL for total PAHs). The presence of this compound in soil should be assessed on the basis of relevant guidelines such as the Health Screening Levels (HSLs) (Friebel & Nadebaum 2011).
* The remaining PAHs are considered non-carcinogenic and include acenaphthene, acenaphthylene, anthracene, fluoranthene, fluorene, phenanthrene and pyrene. Rather than review the toxicity of each individual non-carcinogenic PAH, the published potencies to BaP (or TEFs) available for these PAHs (WHO 1998 and CCME 2008) suggest that individual non-carcinogenic PAHs are at least 100 to 1000 times less toxic/potent than BaP. On this basis a factor of 100 has been applied to the calculated BaP HILs to establish HILs for total PAHs. Review of soil guidelines developed by US EPA (Regional Screening Levels, 2010) indicates that based on consideration of the same pathways of exposure (soil ingestion, dermal contact and inhalation of particulates), health-based guidelines for non-carcinogenic PAHs are at least 10,000 times higher than the BaP guideline. Hence the adoption of a factor of 100 as an additive total for other non-carcinogenic PAHs is considered reasonable.
* The HILs for total PAHs are only relevant provided carcinogenic PAHs meet the BaP HILs and naphthalene also meets the relevant HSLs.

On the basis of the above, the following HILs are recommended for total PAHs (provided carcinogenic PAHs meet the BAP HIL and naphthalene meets the relevant HSL):

|  |  |
| --- | --- |
| **HIL Scenario** | **HIL (mg/kg)** |
|
| Residential A | 300 |
| Residential B | 400 |
| Recreational C | 300 |
| Commercial D | 4000 |

## References

Abdel-Rahman, MS, Skowronski, GA & Turkal, RM 2002, ‘Assessment of the dermal bioavailability of soil-aged benzo(a)pyrene’, *Human and Ecological Risk Assessment,* vol.8, pp. 429–441.

ATSDR 1995, *Toxicological Profile for Polycyclic Aromatic Hydrocarbons (PAHs), (Update)* (PB/95/264370), Agency for Toxic Substances and Disease Registry.

CCME 2008, *Canadian Soil Quality Guidelines, Carcinogenic and Other Polycyclic Aromatic Hydrocarbons (PAHs) (Environmental and Human Health Effects)*, Scientific Supporting Document, PN 1401, Canadian Council of Ministers of the Environment, 2008.

CEPA 1999, *Office of Environmental Health Hazard Assessment (OEHHA) Air Toxics Hot Spots Program Risk Assessment Guidelines, Part II, Technical Support Document for Describing Available Cancer Potency Factors: benzo[a]pyrene,* Californian Environmental Protection Agency.

DEFRA & EA 2002, *Contaminants in Soil: Collation of Toxicological Data and Intake Values for Humans. Benzo(a)pyrene*, Department for Environment, Food and Rural Affairs and the Environment Agency, Bristol, UK.

Fitzgerald, DJ 1991, ‘Setting Response Levels for Polycyclic Aromatic Hydrocarbons (PAHs)’, in El Saadi, O & Langley, A (eds) *The Health Risk Assessment and Management of Contaminated Sites*, Pp. 153−161, Contaminated Sites Monograph Series, South Australian Health Commission, Adelaide, Australia.

Fitzgerald, J 1998, ‘The Benchmark Dose Approach and Health-Based Investigation Level for Polycyclic Aromatic Hydrocarbons (PAHs)’, in Langley, A, Imray, P, Lock, W & Hill, H, Contaminated Sites Monograph Series No. 7, *The Health Risk Assessment and Management of Contaminated Sites,pp. 81−82,* South Australian Health Commission, Adelaide, Australia.

Fitzgerald, DJ, Robinson, NI & Pester, BA 2004, ‘Application of benzo(a)pyrene and coal tar tumour Dose−Response data to a Modified Benchmark Dose Method of Guideline Development’, *Environmental Health Perspectives,* vol. 12(14, pp. 1341−1346.

Friebel, E & Nadebaum, P 2011, *Health screening levels for petroleum hydrocarbons in soil and groundwater. Part 1: Technical development document, Technical Report no. 10*, CRC for Contamination Assessment and Remediation of the Environment, Adelaide, Australia.

Hansen, JB, Oomen, AG, Edelgaard, I & Grøn, C 2007, ‘Oral Bioaccessiblity and Leaching: Tests for Soil Risk Assessment’, *Eng. Life Sci,* vol. 7(2), pp. 170−176.

IARC 2010, *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 92. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures*, International Agency for Research on Cancer, Lyon, France.

Knafla, A, Phillipps, KW, Brecher, RW, Petrovic, S, & Richardson, M 2006, ‘Development of a dermal cancer slope factor for benzo[a]pyrene’, *Regulatory Toxicology and Pharmacology,* vol.45, pp. 159–168.

Knafla, A, Petrovic, S, Richardson, M, Campbell, J, & Rowat, C 2011, ‘Development and application of a skin cancer slope factor for exposures to benzo[a]pyrene in soil’, *Regulatory Toxicology and Pharmacology,* vol. 59 (2011), pp. 101–110.

(MADEP) 2008, *MCP Numerical Standards Development Spreadsheets*, Massachusetts Department of Environmental Protection, available at <http://www.mass.gov/dep/service/compliance/riskasmt.htm>.

MfE 2011, *Toxicological intake values for priority contaminants in soil*, New Zealand Ministry for the Environment, Wellington, New Zealand.

Moody, RP, Joncas, J, Richardson, M & Chu, IH 2007, ‘Contaminated soils(I): In vitro dermal absorption of benzo(a)pyrene in human skin’, *Journal of Toxicology and Environmental Health*, Part A, Vol. 70, pp. 1858–1865.

Neal, J & Rigdon, RH 1967, ‘Gastric tumors in mice fed benzo(a)pyrene: a quantitative study’, *Texas Reports on Biology and Medicine*, vol. 25, pp. 553−557.

NEPC 1999, *Schedule B (7a), Guideline on Health-Based Investigation Levels*, National Envronment Protection (Assessment of Site Contamination) Measure, National Environment Protection Council.

NEPC, 2003, *Polycyclic Aromatic Hydrocarbons (PAHs). Review undertaken as part of the development of the NEPC Air Toxics Measure,* National Environment Protection Council.

NEPC 2004, *National Environmental Protection (Air Toxics) Measure*, National Environment Protection Council.

NHMRC 1999, *Toxicity Assessment for Carcinogenic Soil Contaminants*, National Health and Medical Research Council.

NHMRC 2011, *National water quality management strategy. Australian drinking water guidelines*, National Health and Medical Research Council, Australia.

*New Zealand Ambient Air Quality Guidelines, 2002 Update. Air Quality Report No.32*, Ministry for the Environment and the Ministry of Health, Wellington, New Zealand.

RIVM 2001, *Re-evaluation of human-toxicological Maximum Permissible Risk levels*, National Institute of Public Health and the Environment, Bilthoven, Netherlands, available from: <http://www.rivm.nl/bibliotheek/rapporten/711701025.html>.

Shatkin, J, Mandeera, W, Sean, K &Menzie, CA 2002, ‘Development of a biokinetic model to evaluate dermal absorption of polycyclic aromatic hydrocarbons from soil’, *Human & Ecological Risk Assessment*, vol.8, pp. 713−734.

US EPA 1980, *Ambient Water Quality Criteria for Polynuclear Aromatic Hydrocarbons*, EPA/440/5-90/06g, United States Environment Protection Agency, 1980.

US EPA (IRIS 2012), Data and information available from the *Integrated Risk Information System*, an online database, available from <http://www.epa.gov/iris/>.

US EPA, 2004, *Risk Assessment Guidance for Superfund, Volume I: Human Health Evaluation Manual (Part E, Supplemental Guidance for Dermal Risk Assessment), Final*, EPA/540/R-99/005, OSWER 9285.7-02EP.

US EPA 2005, *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposures to Carcinogens*, EPA/630/R-03/003F,,United States Environment Protection Agency, Washington, DC.

US EPA 2006, *Derivation of RBCs for Carcinogens that Act Via a mutagenic Mode of Action and Incorporate Default ADAFs,* Memo, October 2006, corrected November 2006.

US EPA 2010, *Development of a Relative Potency Factor (RFP) Approach for Polycyclic Aromatic Hydrocarbon (PAH) Mixtures*, in support of Summary Information on the Integrated Risk Information System (IRIS), Draft document.

Wester, RC, Maibach, HI, Bucks, DAW, Sedik, L, Melendres, J, Liao, C & DiZio, D 1990, ‘Percutaneous absorption of [14C] DDT and [14C]benzo[a]pyrene from soil’, *Fundamental and Applied Toxicology,* vol. 15, pp. 510–516.

WHO 1998, *(International Programme on Chemical Safety)– Environmental Health Criteria 202 , Selected Non-Heterocyclic Polycyclic Aromatic Hydrocarbons*, World Health Organization Geneva.

WHO 2000, *Air Quality Guidelines for Europe, 2nd edition,* Publication No. 91, WHO Regional Office for Europe, Copenhagen.

WHO 2010, *WHO Guidelines for Indoor Air Quality, Selected Pollutants*, WHO Regional Office for Europe.

WHO 2011, *Guidelines for drinking-water quality, 4th edn*, World Health Organisation, Geneva, available from <http://www.who.int/water_sanitation_health/dwq/chemicals/en/index.html>.

# Phenol

## General

Several comprehensive reviews of phenol in the environment and its toxicity to humans are available and should be consulted for more detailed information not presented in this summary (ATSDR 2008; WHO 1994; Health Canada, 2000; UK EA 2009). The following provides a summary of the key aspects of phenol that is relevant to the derivation of a soil HIL.

Phenol is a colourless to white to pale pink crystalline solid at room temperature and ambient pressure. Phenol has a distinctive aromatic, somewhat ‘sickening’, sweet and acrid odour. Phenol is soluble in water and miscible with most organic solvents (e.g. acetone and benzene) (ATSDR 2008). Many substituted phenols exist, for example dimethyl and trimethylphenols. These have different toxicities from phenol (ATSDR 2008). The widely varying toxicities and difficulty of making a generic assumption on the likely composition of phenol mixtures mean presenting an HIL representing ‘total phenols’ is considered impractical.

Therefore if substituted phenols may be present, these should be analysed and assessed as separate compounds, rather than on the basis of the phenol HIL.

Phenol can occur naturally in the environment as a product of organic matter decomposition and combustion of wood. Phenol is manufactured for use in phenolic resins, disinfectant and antiseptic and as an intermediate in organic synthesis (ATSDR 2008). Anthropogenic sources of phenol in the environment include vehicle exhaust and waste streams associated with its manufacture. Predominantly, phenol is released as an air emission resulting from venting. Phenol can also be released in the metabolic processes in which it occurs as an intermediate. For example, phenol can be produced from the degradation of organic wastes containing benzene, an organic compound found extensively in the environment. Its primary occurrence as a soil contaminant is in former gas works and coking works sites (ATSDR 2008).

## Previous HIL

The derivation of the previous HIL (HIL A = 8500 mg/kg) for phenol is presented by Turczynowicz (1993) and NEPC (1999). In summary, the HIL was derived on the basis of the following:

* Background intakes were considered in the derivation of the previous HIL with the intakes from food, water and ambient air considered, where available. Due to the lack of available data, the quantification of intakes was limited, hence intakes from contaminated soil were taken to be 25% of the adopted ADI to address these limitations.
* An RfD of 0.6 mg/kg/day referenced from US EPA, based on a NOAEL of 60 mg/kg/day and uncertainty factor of 100 was considered.
* Dermal absorption of phenol was considered to be 12%.
* Oral bioavailability of phenol was considered to be 100%.

Based on intakes derived from soil (ingestion, dermal absorption and dust inhalation) an HIL of 8500 mg/kg was calculated.

## Significance of Exposure Pathways

### Oral Bioavailability

Insufficient data is available to adequately define the bioavailability of phenol in the range of contaminated sites that may need to be considered in Australia. On this basis, a default approach of assuming 100% oral bioavailability has been adopted in the derivation of an HIL. It is noted that a site-specific assessment of bioavailability can be undertaken where required.

### Dermal absorption

ATSDR (2008) notes that phenol is readily absorbed through the skin, and the skin is considered the primary route of entry during occupational exposure (when considered as a product rather than in soil). Dermal absorption of phenol from soil has been shown and maximum phenol penetration was within 2 and 4 hours after application.

No compound-specific dermal absorption value is available for phenol and hence the default value of 0.1 (10%) for semi-volatile compounds available from US EPA (2004) has been adopted.

It is noted that phenol is a skin irritant and skin necrosis has been produced by contact with 1% solutions (UK EA 2009).

### Inhalation of Dust

Phenol is not considered sufficiently volatile to be of significance and inhalation exposures associated with particulates outdoors and indoors are expected to be of less significance than ingestion of soil. While likely to be negligible, potential inhalation exposures associated with dust have been considered in the HIL derived.

### Plant Uptake

Phenols occur naturally in plants and soils. Since phenol and phenolics are relatively water-soluble, they are present in the soil solution and are easily taken up by plants via root absorption and stored in different parts of the plant (CCME 1999). Although it has been shown that plants readily take up phenol, bioaccumulation does not take place, due to a high rate of respiratory decomposition of phenol to CO2. The potential for the uptake of phenol into home-grown produce has been considered in the derivation of HIL A. This has been undertaken on the basis of the equations presented in Appendix B with the following parameters and plant uptake factors estimated:

| **Parameter** | **Value** | **Reference/Comment** |
| --- | --- | --- |
| **Parameters** | | |
| Koc | 187 (cm3/g) | RAIS (2010) |
| log Kow | 1.46 | RAIS (2010) |
| Diffusivity in water | 1.03x10-5 (cm2/s) | RAIS (2010) |
| **Calculated Plant Uptake Factors (mg/kg produce fresh weight per mg/kg soil)** | | |
| Green vegetables | 0.204 | calculated |
| Root vegetables | 0.307 | calculated |
| Tuber vegetables | 0.244 | calculated |
| Tree fruit | 0.00098 | calculated |

It is noted that plants can metabolise phenol readily, hence exposure through eating food derived from plants grown in phenol-containing soil is probably minimal and the above is likely to be conservative.

### Intakes from Other Sources – Background

Background intakes of phenol were estimated in the supporting documentation for the current HIL (Turczynowicz, 1993). Due to the lack of available data, the quantification of intakes was limited, hence intake from contaminated soil was taken to be 25% of the adopted ADI to address these limitations.

No data is available on potential intakes of phenol in Australia from food, water, consumer products and air. Estimates of background intakes by RIVM (2001) suggest intake may be dominated by inhalation exposures and background intakes may comprise 1 µg/kg/day. A more detailed review of background intakes by UK (UK EA 2009) considered intakes from food (dominated by the use of phenol as a flavouring additive), water (insignificant compared with food intakes), air and consumer products where the total intake was estimated to be approximately 390 µg/day (350 µg/day from oral sources and 40 µg/day from inhalation sources) or 5.5 µg/kg/day for a 70 kg adult. These are higher than estimated by Health Canada (2000) where intakes by young children (0.5−4 years) were estimated to be 0.27−0.66 µg/kg/day; these are more consistent with intakes estimated by RIVM (2001).

If the more conservative estimates of background intakes available from the UK (UK EA 2009) were considered, for a child these would comprise approximately 10% of the recommended oral TRV and 25% of the recommended inhalation TRV. A conservative assumption that background intakes comprise approximately 30% (with rounding) of the TRV can be assumed.

## Identification of Toxicity Reference Values

### Classification

The International Agency for Research on Cancer (IARC 1999) has classified phenol as Group 3—not classifiable as to its carcinogenicity.

It is also noted that US EPA (last reviewed in 2002) has classified phenol as Group D—not classifiable as to its carcinogenicity.

### Review of Available Values/Information

Notwithstanding the above, data on carcinogenicity of phenol is inconclusive. For example, RIVM (2001) report that studies in experimental animals suggest phenol can act as a tumour promoter. Further, ATSDR (2008) noted that ‘under certain conditions, especially at high doses, phenol has the potential to be genotoxic. However at the exposure levels likely to occur near hazardous waste sites, phenol is not anticipated to be genotoxic.’ Hence phenol (at least at concentrations expected at contaminated site) is not considered genotoxic. On the basis of the available information, it is considered appropriate that a threshold dose−response approach be adopted for phenol.

Few quantitative toxicity values are available; however the following threshold values are available from Level 1 Australian and International sources:

| **Source** | **Value** | **Basis/Comments** |
| --- | --- | --- |
| **Australian** | | |
| ADWG | No evaluation available |  |
| OCS (2012) | No evaluation available |  |
| **International** | | |
| WHO (2011) | No evaluation available |  |
| WHO (1994) | TDI = 0.06−0.2 mg/kg/day | Based on the range of NOAEL values associated with kidney and developmental effects in rats with the application of an uncertainty factor of 200 to get a range which is the recommended upper limit of the TDI. Some uncertainty is noted with respect to genotoxic potential and hence the evaluation provided is recommended to be periodically reviewed. |
| RIVM (2001) | TDI = 0.04 mg/kg/day  TC = 0.02 mg/m3 | TDI based on a NOAEL of 40 mg/kg/day associated developmental effects in rats, and an uncertainty factor of 900 (and the TDI rounded).  TC is provisional (due to the poor database) and based on a NOAEC of 20 mg/m3 associated with adverse effects in various experimental animals after sub-chronic inhalation exposure, and an uncertainty factor of 1000. |
| Health Canada (2000) | TDI = 0.12 mg/kg/day | TDI based on review of the available database and consideration that developmental effects are the most sensitive end points (noting other end points have limited data). Value derived on the basis of a NOAEL of 12 mg/kg/day for kidney effects (noted to be lower than that from developmental effects) in rats, and an uncertainty factor of 100. Value derived is considered conservative. |
| EC (2006) | No ADI/TDI derived | No ADI/TDI derived however critical data points were identified for systemic toxicity where an oral LOAEL of 1.8 mg/kg/day (based on reduced blood cell count in mice), inhalation LOAEL of 21 mg/m3 (based on possible liver injury in exposed workers) and a dermal NOAEL of 1.18% (equivalent to 130 mg/kg/day) were identified. A NOAEL for developmental toxicity of 93 mg/kg/day was identified from a 2-generation rat study. |
| UK (UK EA 2009) | TDI = 0.7 mg/kg/day  TC = 0.035 mg/m3 | TDI based on review of current studies and evaluations. The TDI is based on a NOAEL of 70 mg/kg/day associated with a 2-generation drinking water rat study, and an uncertainty factor of 100. The study chosen is considered more appropriate that that considered by US EPA, WHO and RIVM as it was of longer duration and associated with drinking water administration (note that phenol exhibited a higher degree of toxicity when given by stomach tube/gavage than when administered via drinking water).  Inhalation value derived on the basis of a LOAEL of 21 mg/m3 (same as identified by EC 2006) associated with potential liver effects in occupationally exposed workersand an uncertainty factor of 600. It is note that the review undertaken considers that the critical effect associated with inhalation exposures to phenol is likely to be its mutagenic potential, and a non-threshold approach may be appropriate, however no evaluations are available. Also noted that despite significant limitations in the available data, it appears that phenol has more toxicity potential via inhalation than when ingested. |
| ATSDR (2008) | No chronic MRL derived | Oral MRL based on a LOAEL of 1 mg/kg/day associated thyroid effects in mink, and an uncertainty factor of 1000 (same study as considered by RIVM). |
| US EPA (2002) | RfD = 0.3 mg/kg/day | RfD (last reviewed in 2002) based on a benchmark dose approach where a BMDL of 93 mg/kg/day associated with decreased maternal weight gain in a short duration developmental rat study was derived, and an uncertainty factor of 300 considered.  The previous evaluation by the US EPA considered an oral RfD of 0.6 mg/kg/day, adopted in the derivation of the current HIL (Turczynowicz 1993). |

While a number of limitations have been identified by the UK review of the available data with respect to the quantification of phenol toxicity (UK EA 2009), the oral value recommended is based on the most recent review where a number of the database deficiencies have been more fully reviewed. This value has been adopted in the derivation of soil HILs.

Few inhalation values are available, and hence the threshold value derived by the UK (UK EA 2009) is recommended as it is based on a more recent review. As inhalation exposures appear to be more toxic than oral exposures the consideration of separate toxicity values for oral and inhalation routes of exposure (even if the inhalation route of exposure is not as significant for the characterisation of contaminated soil issues) is appropriate.

### Recommendation

On the basis of the discussion above, the following toxicity reference values (TRVs) have been adopted for phenol in the derivation of HILs:

**Recommendation for Phenol**

Oral TRV (TRVO) = 0.7 mg/kg/day (UK EA 2009) relevant to oral and dermal routes of exposure

Dermal absorption factor (DAF) = 0.1 (or 10%) (US EPA 2004)

Inhalation TRV (TRVI) = 0.035 mg/m3 (UK EA 2009) relevant to inhalation routes of exposure

Background intakes from other sources (as % of TRV):

BIO = 70% for oral and dermal intakes

BIi = 70% for inhalation

Uptake in home-grown produce considered in derivation of HIL A.

## Calculated HILs

On the basis of the above the following HILs have been derived for phenol (refer to Appendix B for equations used to calculate the HILs and Appendix C for calculations):

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HIL Scenario** | **HIL (mg/kg)** | **Percentage Contribution from Exposure Pathways** | | | |
| **Ingestion of Soil/Dust** | **Ingestion of Home-grown Produce** | **Dermal Absorption of Soil/Dust** | **Inhalation (dust)** |
| Residential A | 3000 | 4 | 91 | 5 | <1 |
| Residential B | 45 000 | 15 | -- | 83 | 2 |
| Recreational C | 40 000 | 27 | -- | 73 | <1 |
| Commercial D | 240 000 | 11 | -- | 87 | 2 |

-- Pathway not included in derivation of HIL

## References

ATSDR 2008, *Toxicological profile for phenol,* US Department of Health and Human Services, Agency for Toxic Substances and Disease Registry, Atlanta, GA, available at: <http://www.atsdr.cdc.gov/toxprofiles/tp115.pdf>.

CCME 1999, *Phenol. Canadian Soil Quality Guidelines for the Protection of Environmental and Human Health*, Canadian Council of Ministers for the Environment.

EC 2006. *European Union Risk Assessment Report: phenol. CAS No: 108-95-2, EINECS No: 203-632-7.* 1st Priority List, Volume 64. EUR 22522 EN/1, Revised edn, European Commission, Brussels, available at: <http://ecb.jrc.it/Documents/Existing-Chemicals/RISK_ASSESSMENT/REPORT/phenolreport060.pdf>.

IARC 1999, *Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Phenol. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans,* vol. 71 (Part 2), International Agency for Research on Cancer, Lyon, France.

Health Canada 2000, *Priority Substances List Assessment Report, Phenol*, Health Canada.

NEPC 1999, *Schedule B (7a), Guideline on Health-Based Investigation Levels, National Environment Protection (Assessment of Site Contamination) Measure*, National Environment Protection Council.

RAIS 2010, Risk Information Assessment System, database maintained by the Oak Ridge Operations Office, available from http:rais.ornl.gov/.

RIVM 2001, *Re-evaluation of human-toxicological Maximum Permissible Risk levels*, National Institute of Public Health and the Environment, Bilthoven, Netherlands, available from: <http://www.rivm.nl/bibliotheek/rapporten/711701025.html>.

Turczynowicz, L 1993, ‘Assessment and Management of Gasworks Sites’, in Langley, A & van Alphen, M (eds), *The Health Risk Assessment and Management of Contaminated Sites, Contaminated Sites Monograph Series, No. 2*, pp. 261−312.

UK EA 2009, *Contaminants in soil: updated collation of toxicological data and intake values for humans, Phenol*, Science report: Sc050021/TOX 9, UK Environment Agency, Bristol, UK.

US EPA 2002, *Toxicological review of Phenol (CAS No. 108-95-2)*, in support of summary information on the Integrated Risk Information System (IRIS), (Appendix A to US EPA, 2002a), US Environmental Protection Agency, Washington, DC, available at: <http://www.epa.gov/iris/toxreviews/0088-tr.pdf#page=132>.

US EPA 2004, *Risk Assessment Guidance for Superfund, Volume I: Human Health Evaluation Manual (Part E, Supplemental Guidance for Dermal Risk Assessment), Final,* EPA/540/R-99/005, OSWER 9285.7-02EP.

WHO 1994, *Environmental Health Criteria Document 161. Phenol,*  International Programme on Chemical Safety, Geneva, available at: <http://www.inchem.org/documents/ehc/ehc/ehc161.htm>.

# Pentachlorophenol (PCP)

## General

Several comprehensive reviews of pentachlorophenol (PCP) in the environment and its toxicity to humans are available and should be consulted for more detailed information not presented in this summary (ATSDR 2001; WHO 1987). The following provides a summary of the key aspects of PCP that are relevant to the derivation of a soil HIL.

Pure pentachlorophenol is a colourless, white or light tan crystalline solid (WHO 1987; ATSDR 2001). It has a characteristic phenolic odour at high temperatures but it is relatively odourless at room temperature. Pentachlorophenol is moderately volatile at ambient temperature and insoluble in water (WHO 1987; ATSDR 2001). Technical grade pentachlorophenol is typically 86% pure and is dark grey to brown in colour as a result of the polychlorinated phenol impurities. It is typically manufactured in the form of dust, beads or flakes (ATSDR 2001).

Pentachlorophenol is an effective biocide and had wide applications in the commercial and agricultural industries as an insecticide (termiticide), fungicide, herbicide, molluscicide and algicide. The primary use of the compound was for wood preservation. In the United States, the use of wood products treated with pentachlorophenol in domestic settings was banned but the compound is still used to preserve power line poles, railroad sleepers, wharf pilings, cross arms and fence posts (ATSDR 2001). Pentachlorophenol was also historically used as a disinfectant, as an ingredient in antifouling paint, as an insecticide or herbicide in domestic environments, in the textile industry, leather industry, in mineral oil and in glue (WHO 1987; ATSDR 2001).

Pentachlorophenol is no longer registered as the active ingredient in any chemical in Australia.

Review of the toxicity of PCP is complicated by the relatively large database on the toxicity of technical-grade PCP and the comparatively small database on pure PCP. Technical-grade PCP has been shown to contain a large number of impurities, including tetrachlorophenols and, to a much lesser extent, polychloro-dibenzodioxins, polychlorodibenzofurans, polychlorodiphenyl ethers, polychloro-phenoxy phenols and chlorinated hydrocarbons. These impurities, in particular the polychloro-dibenzodioxins and furans, are indicated to be responsible for at least some of the observed toxicity of the technical-grade PCP (MfE 2011). Notwithstanding, specific haematopoietic cancer risks are observed with PCP exposure and which are not likely to be due to dioxins or other chlorophenol contaminants (Cooper & Jones 2008).

## Previous HIL

No previous HIL has been derived for PCP (NEPC 1999).

## Significance of Exposure Pathways

### Oral Bioavailability

Insufficient data is available to adequately define the bioavailability of PCP in the range of contaminated sites that may need to be considered in Australia. On this basis, a default approach of assuming 100% oral bioavailability has been adopted in the derivation of an HIL. It is noted that a site-specific assessment of bioavailability can be undertaken where required.

### Dermal absorption

PCP is rapidly absorbed across the skin, and therefore dermal exposure potentially represents a significant route of exposure. The US EPA (2004) has identified a dermal absorption fraction of 0.25 (25%), based on a study by Wester et al. (1993) for PCP in soil. The study found that in vivo absorption in monkeys of PCP in soil was similar to PCP in acetone, with 24% of PCP absorbed over a 24-hour period.

Few other studies are available with quantitative values and hence the dermal absorption value of 0.24 (24%) from Wester et al. (1993) has been used in the derivation of HILs for PCP.

### Inhalation of Dust

PCP is not considered sufficiently volatile to be of significance and inhalation exposures associated with particulates outdoors and indoors are expected to be of less significance than ingestion of soil. While likely to be negligible, potential inhalation exposures associated with dust have been considered in the HIL derived.

### Plant Uptake

In a review paper, McAllister et al. (1996) reported that available data on the plant uptake and transformation of PCP is inconsistent among studies and is inconclusive with regard to the abilities of specific plants to take up the compound. It was observed that the biodegradation of PCP by microorganisms and its adsorption to soil limit the availability of the compound for plant uptake (ATSDR 2001).

Further review by MfE (2011) considered that plant uptake of PCP is not a significant pathway of exposure given that PCP is known to be metabolised by plants (resulting in an over-prediction of plant uptake by the models available), bioconcentration factors relevant to plant uptake are low, and recent papers relating to PCP and plants where uptake is noted are associated with phytoremediation through enhanced microbial activity at plant roots.

On the basis of the above, plant uptake of PCP is not considered significant. In addition, the application of general plant uptake equations is not considered appropriate.

### Intakes from Other Sources – Background

Limited information is available on background exposures to PCP by the general population (PCP intakes have not been addressed in the Australian Total Diet Surveys). PCP is no longer used in Australia and while it is persistent, background levels are expected to be low. Dietary intakes are expected to be the most significant background source (ATSDR 2001). Total intakes of PCP (dominated by food intakes) have been estimated to be between 0.1 and 6 µg/day (equal to 1.4−80 ng/kg/day) (WHO 1987) and 5−35 µg/day (70−500 ng/kg/day) (WHO 2011), though these estimates are based on older data.

ATSDR (2001) notes that intakes estimated from a US total diet survey (1982−1984) suggested intakes for 2-year-old children were up to 48.5 ng/kg/day (about 0.6 µg/day). Estimates from a later total diet survey (1986−1991) suggested lower intakes by children aged 2 years of 1.4 ng/kg/day (about 20 ng/day). Intakes from the later study are consistent with background intakes estimated by RIVM (2001). These intakes are essentially negligible compared with the recommended oral TRV. Hence intakes from other sources have been considered to be negligible.

## Identification of Toxicity Reference Values

### Classification

The International Agency for Research on Cancer (IARC 1991) has classified PCP as Group 2B—possibly carcinogenic to humans.

It is also noted that US EPA has classified PCP as Group B2—probable human carcinogen.

### Review of Available Values/Information

Studies on experimental animals have shown some carcinogenic potential associated with oral exposures to technical grade and mixtures of PCP. However PCP has not demonstrated genotoxicity in in vitro and in vivo test systems and in occupationally exposed humans (RIVM 2001 and NHMRC 2010). Review by ATSDR (2001) and IARC (1991) suggests PCP may exhibit weak clastogenic effects.

Review by MfE (2011) suggested that the data on the genotoxicity of PCP is equivocal, with the strongest indication of genotoxicity (chromosomal effects) occurring in assays with rat microsomal protein (S9). The primary rodent metabolite, tetrahydrochloroquinone (TeHQ), is unambiguously genotoxic. TeHQ does not appear to be a major metabolite of PCP in humans. Furthermore, the majority of PCP appears to be excreted unchanged (ATSDR 2001).

On the basis of the available information, it is considered appropriate that a threshold dose−response approach be adopted for PCP.

Few quantitative toxicity values are available; however the following threshold values are available from Level 1 Australian and International sources:

| **Source** | **Value** | **Basis/Comments** |
| --- | --- | --- |
| **Australian** | | |
| ADWG (NHMRC 2011) | TDI = 0.003 mg/kg/day | The current ADWG (NHMRC 2011) has derived a health-based guideline of 0.01 mg/L, based on a TDI of 0.003 mg/kg/day, noted to be based on a NOEL of 3 mg/kg/day from a 2-year rat study, and an uncertainty factor of 1000 (10 for interspecies extrapolation, 10 for intraspecies variability extrapolation and an additional safety factor of 10 due to the limitations of the toxicological data available at the time the ADI was set). |
| OCS (2012) | No evaluation available |  |
| **International** | | |
| WHO (2011) | No threshold value set | The current WHO DWG (2011) has derived a provisional guideline of 0.009 mg/L based on a US NTP study and a linear multistage model associated with tumour increases and an excess lifetime risk of 10-5 (review unchanged since 1993). It is noted that pentachlorophenol is included in the rolling revisions to the DWG, with no revisions currently available. |
| WHO (1987) | ADI = 0.003 mg/kg/day | References an ADI derived by the National Academy of Sciences which is based on a NOEL of 3 mg/kg/day from a long-term feeding study in rats, and an uncertainty factor of 1000 (same study as considered in the ADWG). |
| RIVM (2001) | TDI = 0.003 mg/kg/day | TDI based on a LOAEL of 1 mg/kg/day associated with thyroid effects in mink, and an uncertainty factor of 300. |
| ATSDR (2001) | MRL = 0.001 mg/kg/day | Oral MRL based on a LOAEL of 1 mg/kg/day associated with thyroid effects in mink, and an uncertainty factor of 1000 (same study as considered by RIVM. |
| US EPA (IRIS 2012) | RfD = 0.005 mg/kg/day | RfD (reviewed in 2010) based on a LOAEL of 1.5 mg/kg/day associated hepatotoxicity, including dose-related increases in incidence and severity of hepatocellular pigmentation, cytoplasmic vacuolation, and chronic inflammation, and significant increases in relative liver weight and increases in absolute liver weight (significant in females), observed in a chronic oral study in dogs (Mecler 1996). An uncertainty factor of 300 was applied. US EPA has also derived a non-threshold oral slope factor not considered relevant here. |

While different key studies were considered by the various agencies noted above, use of these studies has largely resulted in the derivation of oral toxicity reference values that are essentially the same (ranging from 0.001 to 0.005 mg/kg/day). Hence the threshold reference value adopted in the ADWG (NHMRC 2011), which is consistent with that derived by all other agencies, including ATSDR, US EPA and RIVM, is recommended.

No dermal or inhalation specific studies or data are available. For the presence of PCP in soil it is considered appropriate to consider use of the available TDI for all pathways of exposures.

### Recommendation

On the basis of the discussion above, the following toxicity reference values (TRVs) have been adopted for PCP in the derivation of HILs:

**Recommendation for Pentachlorophenol**

Oral TRV (TRVO) = 0.003 mg/kg/day (NHMRC 2011) relevant to all pathways of exposure

Dermal absorption factor (DAF) = 0.24 (or 24%) (Wester et al. 1993)

Background intakes from other sources (as % of TRV):

BIO = 0% for oral and dermal intakes

BIi = 0% for inhalation

## Calculated HILs

On the basis of the above, the following HILs have been derived for PCP (refer to Appendix B for equations used to calculate the HILs and Appendix C for calculations):

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HIL Scenario** | **HIL (mg/kg)** | **Percentage Contribution from Exposure Pathways** | | | |
| **Ingestion of Soil/Dust** | **Ingestion of Home-grown Produce** | **Dermal Absorption of Soil/Dust** | **Inhalation (dust)** |
| Residential A | 100 | 24 | -- | 76 | <1 |
| Residential B | 130 | 7 | -- | 93 | <1 |
| Recreational C | 120 | 13 | -- | 87 | <1 |
| Commercial D | 660 | 5 | -- | 95 | <1 |

-- Pathway not included in derivation of HIL

## References

ATSDR 2001, *Toxicological profile for Pentachlorophenol*, Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services, Atlanta, Georgia, USA.

Cooper, GS & Jones, S 2008, ‘Pentachlorophenol and cancer risk: focusing the lens on specific chlorophenols and contaminants’. *Environmental Health Perspectives,* vol. 116, pp. 1001−1008.

IARC 1991, - *Summaries & Evaluations, Pentachlorophenol*, vol. 53 (1991), p. 371, International Agency for Research on Cancer, Lyon, France.

McAllister, KA, Lee, H & Trevore, JT 1996, ‘Microbial degradation of pentachlorophenol’, *Biodegradation,* vol. , pp. 1−40.

Mecler, F 1996, *Fifty-two week repeated dose chronic oral study of* ***pentachlorophenol*** *administered via capsule to dogs*, Study conducted by TSI Mason Laboratories, Worcester, MA, TSI Report #ML-PTF-J31-95-94. Submitted to the **Pentachlorophenol** Task Force, c/o SRA International, Inc., Washington, DC. U.S. Environmental Protection Agency, Washington, DC; MRID 439827-01, unpublished report.

MfE 2011, *Toxicological intake values for priority contaminants in soil*, New Zealand Ministry for the Environment, Wellington, New Zealand.

NEPC 1999, *Schedule B (7a), Guideline on Health-Based Investigation Levels, National Environment Protection (Assessment of Site Contamination) Measure*, National Environment Protection Council, Australia.

NHMRC 2010, *Cancer Risk Assessment Methodology:  A Review and Recommendations,* September 2010, report prepared by NHMRC for NEPC, Adelaide, Australia.

NHMRC 2011, *National water quality management strategy. Australian drinking water guidelines*, National Health and Medical Research Council, Australia.

RIVM 2001, *Re-evaluation of human-toxicological Maximum Permissible Risk levels*, National Institute of Public Health and the Environment, Bilthoven, Netherlands, available from: <http://www.rivm.nl/bibliotheek/rapporten/711701025.html>.

US EPA (IRIS 2012), Data and information available from the *Integrated Risk Information System*, an online database, available from <http://www.epa.gov/iris/>.

US EPA 2004, *Risk Assessment Guidance for Superfund, Volume I: Human Health Evaluation Manual (Part E, Supplemental Guidance for Dermal Risk Assessment), Final*, EPA/540/R-99/005, OSWER 9285.7-02EP.

Wester, RC, Maibach, HI, Sedik, L, Melendres, J, Wade, M & Dizio, S 1993, ‘Percutaneous Absorption of Pentachlorophenol from Soil’, *Fundamental & Applied Toxicology*, vol. 20, No. 1, pp. 68−71.

WHO 1987, *Environmental Health Criteria No 71, Pentachlorophenol*.World Health Organisation*,* Geneva.

WHO 2011, *Guidelines for drinking-water quality, 4th edition*, World Health Organisation, Geneva, available from <http://www.who.int/water_sanitation_health/dwq/chemicals/en/index.html>.

# Total Cresols

## General

Several comprehensive reviews of cresols in the environment and their toxicity to humans are available and should be consulted for more detailed information not presented in this summary (ATSDR 2008; WHO 1995). The following provides a summary of the key aspects of cresols that are relevant to the derivation of a soil HIL.

Cresols are a group of isomers comprising a single benzene ring, a hydroxyl group and a methyl group (C7H8O). There are three structural isomers, including m-cresol (2-methylphenol), p-cresol (3-methylphenol), and o-cresol (4-methylphenol). These isomers may occur separately or as a mixture (ATSDR 2008). In their pure form, cresols are colourless solids, while mixtures are more commonly liquids. Cresols are semi-volatile compounds with moderate solubility in water and a medicinal-type odour (ATSDR 2008). The abundance of p-cresols in the environment is significantly greater than that of the alternative isomers, as is the abundance of o-cresol relative to that of m-cresols. However, there is a greater amount of information and studies surrounding the health effects associated with m- and o-cresols. It should be noted that the behaviour of all three isomers in the environment is considered to be similar.

Cresols are both a naturally occurring and manufactured group of chemicals that may be used as solvents, disinfectants, deodorisers, wood preservatives and to make other chemicals (ATSDR 2008). O-cresol is used in the manufacture of several dye intermediates (ATSDR 2008). P-cresol is predominantly used in the manufacture of anti-oxidants, synthetic food flavours and fragrances, and m-cresol is used in the synthesis of many herbicides and insecticides (ATSDR 2008). Cresols occur in various plant oils including peppermint, sandalwood, jasmine, Easter lily, ylang ylang, eucalyptus and camphor.

## Previous HIL

No previous HIL is available for cresols (NEPC 1999).

## Significance of Exposure Pathways

### Oral Bioavailability

Insufficient data is available to adequately define the bioavailability of cresols in the range of contaminated sites that may need to be considered in Australia. On this basis, a default approach of assuming 100% oral bioavailability has been adopted in the derivation of an HIL. It is noted that a site-specific assessment of bioavailability can be undertaken where required.

### Dermal absorption

Insufficient data is available on the dermal absorption of cresols from soil. Hence the default values of 0.1 (10%) suggested by US EPA (2004) for semi-volatiles has been adopted in the derivation of HILs.

### Inhalation of Dust

Cresols are not considered sufficiently volatile to be of significance and inhalation exposures associated with particulates outdoors and indoors are expected to be of less significance than ingestion of soil. While likely to be negligible, potential inhalation exposures associated with dust have been considered in the HIL derived.

### Plant Uptake

No data is available on the potential for the uptake of cresols into edible fruit and vegetable crops. Limited data is also available on the potential or cresols to bioaccumulate. Cresols are soluble in water and, based on Koc values referenced by OECD SIDS (2003), there is a low sorption potential for cresols. Hence, while specific data is lacking, there is the potential for cresols to be available in soil water to be taken up by plants.

Hence a conservative approach has been taken to consider the potential for the uptake of cresols into home-grown produce in the derivation of HIL A. This has been undertaken on the basis of the equations presented in Appendix B, with the following parameters and plant uptake factors estimated:

| **Parameter** | **Value** | **Reference/Comment** |
| --- | --- | --- |
| **Parameters** | | |
| Koc | 307 (cm3/g) | RAIS (2010) |
| log Kow | 1.95 | RAIS (2010) |
| Diffusivity in water | 9.78x10-6 (cm2/s) | RAIS (2010) |
| **Calculated Plant Uptake Factors (mg/kg produce fresh weight per mg/kg soil)** | | |
| Green vegetables | 0.18 | calculated |
| Root vegetables | 0.255 | calculated |
| Tuber vegetables | 0.152 | calculated |
| Tree fruit | 0.00044 | calculated |

### Intakes from Other Sources – Background

Limited information is available on background exposures to cresols by the general population. Available reviews by ATSDR (2008), OECD SIDS (2003) and RIVM (2001) have not been able to quantify background intakes due to a lack of data. As data is lacking for background intakes of cresols, an estimate or default value can be assumed. Cresols are expected to be widely present in the environment and hence a value of 50% may be relevant where data are not available.

## Identification of Toxicity Reference Values

### Classification

The International Agency for Research on Cancer (IARC) has not classified cresol with respect to human carcinogenicity.

US EPA has classified cresols as Group C−possible human carcinogen.

### Review of Available Values/Information

There is no adequate data available to assess carcinogenicity of cresols. One study suggests cresols may promote skin tumours. Genotoxicity of cresols has been evaluated (ATSDR 2008) and the weight of evidence suggests that ‘cresols do not pose a genotoxic threat to humans under normal environmental exposure conditions’. On the basis of the available information, it is considered appropriate that a threshold dose-response approach be adopted for cresols.

Few quantitative toxicity values are available, however the following are available from Level 1 Australian and International sources:

| **Source** | **Value** | **Basis/Comments** |
| --- | --- | --- |
| **Australian** | | |
| ADWG | No evaluation available |  |
| OCS (2012) | No evaluation available |  |
| **International** | | |
| WHO (1995) | ADI = 0.17 mg/kg/day | ADI derived by WHO (1995) on a NOAEL of 50 mg/kg/day from a sub-chronic study and a 300-fold uncertainty factor (which included an additional 10 fold factor to address the lack of chronic studies and possible genotoxic and promoting activity). |
| RIVM (2001) | TDI = 0.05 mg/kg/day  TC = 0.17 mg/m3 | TDI based on a 90-day sub-chronic oral study.  TC based on route extrapolation from oral data. |
| OEHHA (2009) | REL = 0.6 mg/m3 | Chronic REL based on route extrapolation of the LOAEL and NOAEL derived from the study used to derive the current US EPA RfD for 2- and 3-methylphenol. |
| ATSDR (2008) | MRL = 0.1 mg/kg/day | Oral MRL based on a LOAEL associated with increased incidences of bronchiole hyperplasia of the lung and follicular degeneration of the thyroid gland from a 2-year dietary study in female mice (NTP 2008). |
| US EPA (IRIS 2012) | RfD = 0.05 mg/kg/day | RfD (last reviewed in 1988) derived for 2- and 3-methylphenol based on decreased body weights and neurotoxicity in a 90-day sub-chronic study in rats. |

The threshold value derived by ATSDR (2008) is based on a chronic study not available at the time when the WHO (1995), RIVM (2001) or US EPA conducted their review (where threshold values were derived on the basis of sub-chronic studies). On this basis, the oral value (taken as an ADI) available from ATSDR (2008) is considered the most current and robust value for deriving a soil HIL.

No dermal or inhalation specific studies or data are available. For the presence of cresols in soil, it is considered appropriate to consider use of the available ADI for all pathways of exposures.

### Recommendation

On the basis of the discussion above, the following toxicity reference values (TRVs) have been adopted for cresols (as sum of all isomers) in the derivation of HILs:

**Recommendation for Cresols**

Oral TRV (TRVO) = 0.1 mg/kg/day (ATSDR 2008) relevant to all pathways of exposure

Dermal absorption factor (DAF) = 0.1 (or 10%) (US EPA 2004)

Background intakes from other sources (as % of TRV):

BIO = 50% for oral and dermal intakes

BIi = 50% for inhalation

Uptake in home-grown produce considered in derivation of HIL A.

## Calculated HILs

On the basis of the above, the following HILs have been derived for cresols (refer to Appendix B for equations used to calculate the HILs and Appendix C for calculations):

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HIL Scenario** | **HIL (mg/kg)** | **Percentage Contribution from Exposure Pathways** | | | |
| **Ingestion of Soil/Dust** | **Ingestion of Home-grown Produce** | **Dermal Absorption of Soil/Dust** | **Inhalation (dust)** |
| Residential A | 400 | 5 | 89 | 6 | <1 |
| Residential B | 4700 | 16 | -- | 84 | <1 |
| Recreational C | 4000 | 27 | -- | 73 | <1 |
| Commercial D | 25 000 | 12 | -- | 88 | <1 |

-- Pathway not included in derivation of HIL

## References

ATSDR 2008, *Toxicological profile for Cresols*, Agency for Toxic Substances and Disease Registry U.S. Department of Health and Human Services, Atlanta, Georgia, USA, available from <http://www.atsdr.cdc.gov/ToxProfiles/tp.asp?id=946&tid=196>.

NEPC 1999, *Schedule B (7a), Guideline on Health-Based Investigation Levels, National Environment Protection (Assessment of Site Contamination) Measure*, National Environment Protection Council, Australia.

NHMRC 2011, *National water quality management strategy, Australian drinking water guidelines*, National Health and Medical Research Council, Australia.

NTP 2008, *Toxicology and carcinogenesis studies of cresols (CAS No. 1319-77-3) in male F344/N rats and female B6C3F1 mice (feed studies)*, National Toxicology Program, TR-550, Draft technical report, Research Triangle Park, NC.,

OECD SIDS 2003, *M/P-Cresol Category. SIDS Initial Assessment Report,* for SIAM 16.

OEHHA 2009, *Air Toxicology and Epidemiology, summary of current Reference Exposure Levels and Cancer Potency Factors*, available from Office of Environmental Health Hazard Assessment (OEHHA), http://www.oehha.org/air/toxic\_contaminants/index.html.

RAIS (n.d.), *Risk Assessment Information System*, website and database maintained by the Oak Ridge Operations Office, available from: <http://rais.ornl.gov/>.

RIVM 2001, *Re-evaluation of human-toxicological Maximum Permissible Risk levels*, National Institute of Public Health and the Environment, Bilthoven, Netherlands, .available from: <http://www.rivm.nl/bibliotheek/rapporten/711701025.html>.

US EPA (IRIS 2012), Data and information available from the *Integrated Risk Information System*, an online database, available from <http://www.epa.gov/iris/>.

US EPA 2004, *Risk Assessment Guidance for Superfund, Volume I: Human Health Evaluation Manual (Part E, Supplemental Guidance for Dermal Risk Assessment), Final*, EPA/540/R-99/005, OSWER 9285.7-02EP.

WHO 1995, *Environmental Health Criteria 168, Cresols*. International Programme on Chemical Safety, World Health Organization, Geneva.

# Shortened forms

|  |  |
| --- | --- |
| **ADI** | acceptable daily intake |
| **ADAF** | adjustment factor |
| **ADWG** | Australian Drinking Water Guidelines |
| **AI** | adequate intake |
| **ANZECC** | Australia and New Zealand Environment and Conservation Council |
| **APVMA** | Australian Pesticides and Veterinary Medicines Authority |
| **ATDS** | Australian Total Diet Survey |
| **ATSDR** | Agency for Toxic Substances and Disease Registry |
| **BA** | bioavailability |
| **BAP** | benzo(a)pyrene |
| **BI** | background intake |
| **BMD** | benchmark dose |
| **BMDL** | Benchmark dose lower confidence limit |
| **CCME** | Canadian Council of Ministers of the Environment |
| **CICAD** | Concise International Chemicals Assessment Document |
| **CNS** | central nervous system |
| **DAF** | dermal absorption factor |
| **DW** | dry weight |
| **DWG** | drinking water guidelines |
| **EA** | Environment Agency (England and Wales) |
| **EHC** | Environmental Health Criteria |
| **EPA** | Environment Protection Authority |
| **FSANZ** | Food Standards Australia New Zealand |
| **GAF** | gastrointestinal absorption factor |
| **HEC** | human equivalent concentration |
| **HED** | human equivalent dose |
| **HIARC** | Hazard Identification Assessment Review Committee |
| **HIL** | health investigation level |
| **HSDB** | Hazardous Substances Data Bank |
| **HSL** | health screening level |
| **IARC** | International Agency for Research on Cancer |
| **IEUBK** | Integrated exposure uptake biokinetic model |
| **IRIS** | Integrated Risk Information System |
| **JECFA** | Joint FAO/WHO Expert Committee on Food Additives |
| **JMPR** | WHO/FAO Joint Meeting on Pesticide Residues |
| **LOAEL** | lowest observed adverse effect level |
| **LOEL** | lowest observed effect level |
| **MF** | modifying factor |
| **MOA** | mode (or mechanism) of action |
| **MRL** | minimal risk level |
| **NEPC** | National Environment Protection Council |
| **NEPM** | National Environment Protection Measure |
| **NHMRC** | National Health and Medical Research Council |
| **NOAEL** | no observable adverse effect level |
| **NOEL** | no observable effect level |
| **NSW DECC** | New South Wales Department of Environment and Climate Change |
| **OCS** | Office of Chemical Safety |
| **OEHHA** | Office of Environmental Health Hazard Assessment |
| **PAH** | polycyclic aromatic hydrocarbon |
| **PCP** | pentachlorophenol |
| **PTDI** | provisional tolerable daily intake |
| **PTMI** | provisional tolerable monthly intake |
| **PTWI** | provisional tolerable weekly intake |
| **RAIS** | Risk Assessment Information System |
| **RDI** | recommended daily intake |
| **REL** | reference exposure level |
| **RfC** | reference concentration |
| **RfD** | reference dose |
| **RME** | reasonable maximum exposure |
| **SF** | slope factor |
| **TC** | tolerable concentration |
| **TDI** | tolerable daily intake |
| **TEF** | toxicity equivalence factor |
| **TRV** | toxicity reference value |
| **UF** | uncertainty factor |
| **UL** | upper limit |
| **UR** | unit risk |
| **US EPA** | United States Environmental Protection Agency |
| **WHO** | World Health Organization |
| **WHO DWG** | World Health Organization Drinking Water Guidelines |

1. Based on guidance available from US EPA (2005), early lifetime exposures have been accounted for by the application of adjustment factors (ADAFs) to calculate the risk for different life stages: risk during the first 2 years of life (ADAF = 10); risk for ages 2 through to less than 16 years (ADAF = 3); and the risk for ages 16 through to 70 years (ADAF = 1). The total calculated risk for a lifetime is the sum of risk over all life stages. [↑](#footnote-ref-1)